A GLP-1 receptor agonist — Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, the new oral versions — doesn't just affect your gut. The gut is the mechanism. The drug slows gastric emptying, alters intestinal motility, and acts on the same gut-brain pathway that governs your appetite, your energy, and your mood. That's why it works for weight. It's also why up to 44% of users report nausea, ~30% report diarrhea, ~24% report constipation, and 13% of all stoppers quit because of side effects.
A May 2026 study in medRxiv showed semaglutide induces a proinflammatory gut microbiome signature that persists after the drug stops — and appears to drive post-cessation weight regain. The drug touches three gut systems: the lining (motility, barrier integrity), the microbiome (diversity, dysbiosis), and the gut-brain connection (serotonin, signaling, energy).
Of the 18 GLP-1-positioned gut products we tested, 14 only supported one of those three systems. Three supported two. One supported all three. That single product is why this analysis exists.
The three things a GLP-1 does to your gut — and the three checkpoints every companion product gets graded on. Miss any one and the bottle is doing less than the label implies.
GLP-1s slow gastric emptying — that's how they work. But food sitting longer means the intestinal lining is under constant pressure, and the result is bloating, distension, and that brick-in-the-stomach feeling. A real GLP-1 companion supplement supports the lining with demulcent botanicals: Aloe Vera, Slippery Elm, Marshmallow Root, Deglycyrrhizinated Licorice Root, plus chelated Zinc and MSM for barrier integrity. 11 of 18 products we tested ignored the lining entirely.
The May 2026 microbiome study is the headline finding here: GLP-1s reduce microbial diversity and the dysbiosis persists after the drug stops. The category response has been single-strain probiotics — most of which are destroyed by stomach acid before they reach the gut. The real companion answer is spore-based probiotics (Bacillus coagulans, Bacillus subtilis) that are acid-resistant by design and actually arrive alive, plus prebiotics to feed them. Probiotics are a third of the answer, not the whole answer.
About 90% of your serotonin is made in the gut. GLP-1s act on the brain's appetite center while simultaneously altering the gut signaling that produces mood and energy neurotransmitters. The user-side experience: brain fog, the 2pm wall that doesn't lift, that flat feeling some GLP-1 users describe but can't name. The companion support category is mostly silent here. Lion's Mane and Turkey Tail mushrooms are the two functional ingredients with the most consistent gut-brain research behind them.
Side-by-side across lining support, microbiome support, and gut-brain support. The single-system limit disqualified 14 of 18 products before format or price entered the conversation.
| Fused Gut Master |
Seed DS-01 |
ARMRA Colostrum |
Metamucil Fiber |
AG1 Greens |
|
|---|---|---|---|---|---|
#1 Pick
|
![]() |
![]() |
![]() |
![]() |
|
| System 1: Lining | |||||
| System 2: Microbiome | |||||
| System 3: Gut-Brain | |||||
| Acid-resistant spore probiotics | |||||
| Format | 2 gummies | 4 capsules | Powder | Powder | Powder |
| Daily cost | $1.17 | $1.99 | $2.32 | $0.50 | $2.63 |
| Score | 9.6 | 8.1 | 7.8 | 5.9 | 6.4 |
Each product evaluated against the three-system test, then against format, cost, and clinical support. Score reflects how completely the formula addresses the gut systems a GLP-1 actually disrupts — not brand recognition or marketing spend.
GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone produced in the intestinal L-cells. The drug version stays active in the body for days instead of minutes. Its primary mechanism is slowing gastric emptying — food sits longer, fullness lasts longer, calorie intake drops. That's the appetite effect. It's also the source of every common gut side effect.
The peer-reviewed picture: a systematic review of 38 studies in Nutrients (April 2025) concluded GLP-1 analogues produce notable changes in the composition, richness, and diversity of the gut microbiome. A May 2026 medRxiv preprint went further — semaglutide-treated subjects developed a proinflammatory gut microbiome signature that persisted after the drug stopped, and fecal microbiome transplants from semaglutide-treated mice transferred gut barrier impaction, low-grade inflammation, and accelerated fat accumulation to germ-free recipient mice. That dysbiosis appears to causally drive the weight regain ~75% of GLP-1 users experience after stopping.
On the lining: GLP-1 receptor agonists do not directly stimulate the GLP-2 pathway, which is the system that normally supports intestinal mucosal growth and barrier integrity. So GLP-1 users may have a relatively under-supported gut lining compared to baseline, on top of the slowed-motility pressure. On the gut-brain side: about 90% of the body's serotonin is produced in the gut, and the drug's direct CNS action plus the indirect microbiome dysbiosis hits gut-brain signaling from two directions simultaneously. Brain fog and energy flatness in GLP-1 users are not imagined. They have a mechanism.
What this means for companion supplementation is concrete. A single-system product — microbiome only, or fiber only, or general nutrition only — addresses one piece of a three-piece problem. The category response so far has been to fragment: separate protein products for muscle loss, separate fiber for constipation, separate probiotics for microbiome support. A formula that supports all three gut systems at once is what the mechanism actually calls for.
Reported outcomes from Gut Master users currently on a GLP-1. Individual experience varies — this is a supplement, not a medication, and it doesn't override the drug's direct effects.
Aloe Vera, Slippery Elm, and Marshmallow Root start forming a soothing layer over the GI tract within the first several days. Most users report that the post-meal pressure and brick-in-the-stomach feeling start easing first. Bloating starts to feel less constant.
Spore probiotics have arrived alive in the intestine and started doing their work. Bathroom rhythm becomes more predictable — for many users this is the most concrete signal that something has shifted. Whatever pattern your GLP-1 was producing (constipated, urgent, or all over the place) starts settling toward regular.
The gut-brain layer takes the longest to register. Lion's Mane and Turkey Tail support the connection that produces steady afternoon energy and clearer thinking. Users frequently describe this as "I forgot I was bloated" rather than a dramatic moment — the absence of the problem becomes the proof.
All three systems supported continuously. Most subscribers describe this as their new normal — stomach stops being something they think about, energy doesn't crash in the afternoon, the drug can do its job without the gut taking the daily hit. The 30-Day "Feel Lighter" Guarantee is in place if it doesn't deliver.
Lining. Microbiome. Gut-brain connection. One formula. Two pineapple mango gummies a day. Built for the person whose drug was working — but their gut wasn't.
The GLP-1 Companion Report is an independent editorial publication covering supplements and lifestyle products marketed to GLP-1 users. We may earn a commission on purchases made through links on this page. Commissions do not influence rankings — rankings are based on the three-system test methodology described above, applied to publicly available Supplement Facts panels and product specifications as of May 2026.
Nothing on this page is medical advice. Statements have not been evaluated by the FDA. Products mentioned are not intended to diagnose, treat, cure, or prevent any disease, condition, or side effect of any medication, including GLP-1 receptor agonists. Always consult your prescribing clinician before adding any supplement to a routine that includes prescription medication.
Brand names and trademarks (Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Saxenda®, Seed®, ARMRA®, Metamucil®, AG1®) are the property of their respective owners and are referenced here solely for editorial comparison purposes.